Federal contract award
75A50122F33004
INTEGRATED SAFETY SUMMARY REPORT OF CLINICAL STUDIES ASSESSING SAFETY OF INFLUENZA VACCINES ADMINISTERED WITH AS03 OR MF59 ADJUVANT.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | 75A50120D00015 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $3.0M |
| Current contract value | $3.0M |
| Potential contract value / ceiling | $3.0M |
| Start date | Sep 27, 2022 |
| Current end date | Sep 26, 2026 |
| Potential end date | Sep 26, 2026 |
| Latest award activity | Jul 22, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 22, 2026 | P00005 | $0 | EO 14398. INTEGRATED SAFETY SUMMARY REPORT OF CLINICAL STUDIES ASSESSING SAFETY OF INFLUENZA VACCINES ADMINISTERED WITH AS03 OR MF59 ADJUVANT. |
| Oct 22, 2025 | P00004 | $0 | INTEGRATED SAFETY SUMMARY REPORT OF CLINICAL STUDIES ASSESSING SAFETY OF INFLUENZA VACCINES ADMINISTERED WITH AS03 OR MF59 ADJUVANT. |
| Sep 24, 2025 | P00003 | $0 | INTEGRATED SAFETY SUMMARY REPORT OF CLINICAL STUDIES ASSESSING SAFETY OF INFLUENZA VACCINES ADMINISTERED WITH AS03 OR MF59 ADJUVANT. |
| May 6, 2024 | P00002 | $0 | INTEGRATED SAFETY SUMMARY REPORT OF CLINICAL STUDIES ASSESSING SAFETY OF INFLUENZA VACCINES ADMINISTERED WITH AS03 OR MF59 ADJUVANT. |
| Jan 24, 2023 | P00001 | $0 | INTEGRATED SAFETY SUMMARY REPORT OF CLINICAL STUDIES ASSESSING SAFETY OF INFLUENZA VACCINES ADMINISTERED WITH AS03 OR MF59 ADJUVANT. |
| Sep 27, 2022 | 0 | $3.0M | INTEGRATED SAFETY SUMMARY REPORT OF CLINICAL STUDIES ASSESSING SAFETY OF INFLUENZA VACCINES ADMINISTERED WITH AS03 OR MF59 ADJUVANT. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.